Pulmonary artery denervation research: a news article previewing a randomized clinical trial report on adding an interventional therapy to standard care, inviting readers to examine the study design, scope, and implications for treating pulmonary hypertension linked to left heart disease.
Key Takeaways
- This highly anticipated publication marks a watershed moment for cardiovascular interventions
- Trial was designed to evaluate the safety and clinical efficacy of adding Pulmonary Artery Denervation (PADN)
- Effect was sustained through the follow-up period, which is clinically relevant for this chronic, progressive disease